secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001326732-26-000023
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Xencor receives Genentech/Roche termination notice for collaboration; effective Sept 4, 2026
--------------------------------------------------------------------------------

- Genentech terminated Amended and Restated Collaboration & License Agreement for convenience, effective September 4, 2026.
- Sole active product, efbalropendekin alfa, was removed from Roche's pipeline in January 2025.
- Xencor ceased cost-sharing in H1 2024; Genentech assumed sole responsibility for development activities.
- Termination had been anticipated after Roche's January 2025 pipeline announcement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673226000023/0001326732-26-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673226000023/xncr-20260304.htm
  HTML page:      https://secwatch.observer/filing/0001326732-26-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer